ReviewThe journal of allergy and clinical immunology. In practice2013
Severe asthma: an expanding and mounting clinical challenge.
Review in The journal of allergy and clinical immunology. In practice, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Microplastics as environmental modifiers of lung disease.EMBO molecular medicine · 2026Review
- Biomarker-Defined Endotypes and Clinical Phenotypes of Asthma: A Cluster-Based Analysis of Type-2 Inflammatory Patterns and Their Clinical Correlates.Journal of asthma and allergy · 2026Article
- Identification of clinically meaningful, overlapping obstructive respiratory disease subtypes via data-driven approaches in a primary care population.BMC pulmonary medicine · 2025Article
- Presence of sputum IgG against eosinophilic inflammatory proteins in asthma.Frontiers in immunology · 2024Article
- Defining pediatric asthma: phenotypes to endotypes and beyond.Pediatric research · 2021Review
- Relationship between CCR5Postepy dermatologii i alergologii · 2021Article
- β-Glucan exacerbates allergic asthma independent of fungal sensitization and promotes steroid-resistant TThe Journal of allergy and clinical immunology · 2017Article
- A combination of dexamethasone and anti-IL-17A treatment can alleviate diesel exhaust particle-induced steroid insensitive asthma.The Journal of allergy and clinical immunology · 2016Article
- Regulation of CBL and ESR1 expression by microRNA-22‑3p, 513a-5p and 625-5p may impact the pathogenesis of dust mite-induced pediatric asthma.International journal of molecular medicine · 2016Article
- Polyunsaturated lysophosphatidic acid as a potential asthma biomarker.Biomarkers in medicine · 2016Review
- Vanin-1 expression and methylation discriminate pediatric asthma corticosteroid treatment response.The Journal of allergy and clinical immunology · 2015Article
- Airway Inflammation after Bronchial Thermoplasty for Severe Asthma.Annals of the American Thoracic Society · 2015Observational
- Collaborative interactions between type 2 innate lymphoid cells and antigen-specific CD4+ Th2 cells exacerbate murine allergic airway diseases with prominent eosinophilia.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs.Biomarker insights · 2015Review
- Omega-3 Fatty Acids Supplementation in Children to Prevent Asthma: Is It Worthy?-A Systematic Review and Meta-Analysis.Journal of allergy · 2015Review
- An overview of integrative therapies in asthma treatment.Current allergy and asthma reports · 2014Review
- Safety and efficacy of bronchial thermoplasty in refractory asthma with severe obstructive respiratory dysfunction.Therapeutic advances in respiratory diseaseObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Although all patients with asthma have variable airflow obstruction, airway inflammation, and bronchial hyperresponsiveness, some have disease that is severe in many aspects: persistent airflow obstruction, ongoing symptoms, increased frequency of exacerbations, and, most importantly, a diminished response to medications. A number of definitions have emerged to characterize the clinical features of severe asthma, but a central feature of this phenotype is the need for high doses of medications, especially corticosteroids, in attempts to achieve disease control. The prevalence of severe asthma is also undergoing reevaluation from the usual estimate of 10% to larger numbers on the basis of medication needs and the lack of disease control achieved. At present, the underlying mechanisms of severe asthma are not established but likely reflect a heterogeneous pattern, rather than a single unifying process. Guideline-directed treatment for severe asthma has limits with usual approaches centered on high doses of inhaled corticosteroids, long-acting β-agonists, and trials with omalizumab, the monoclonal antibody to IgE. With the development of approaches to recognize asthma phenotypes with distinct pathogenesis and hence unique therapeutic targets, it is hoped that a personalized strategy in treatment directed toward disease-specific features will improve outcomes for this high-risk, severely affected population of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.